- Home
- CANF vs GIPR Comparison
CANF vs GIPR Comparison
Compare CANF & GIPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- GIPR
- Stock Information
- Founded
- CANF 1994
- GIPR 2015
- Country
- CANF Israel
- GIPR United States
- Employees
- CANF N/A
- GIPR N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- GIPR Real Estate Investment Trusts
- Sector
- CANF Health Care
- GIPR Real Estate
- Exchange
- CANF Nasdaq
- GIPR Nasdaq
- Market Cap
- CANF 9.4M
- GIPR 9.7M
- IPO Year
- CANF N/A
- GIPR 2021
- Fundamental
- Price
- CANF $1.81
- GIPR $1.72
- Analyst Decision
- CANF Strong Buy
- GIPR Hold
- Analyst Count
- CANF 2
- GIPR 1
- Target Price
- CANF $14.00
- GIPR N/A
- AVG Volume (30 Days)
- CANF 122.9K
- GIPR 34.9K
- Earning Date
- CANF 03-04-2025
- GIPR 04-08-2025
- Dividend Yield
- CANF N/A
- GIPR 9.07%
- EPS Growth
- CANF N/A
- GIPR N/A
- EPS
- CANF N/A
- GIPR N/A
- Revenue
- CANF $667,000.00
- GIPR $10,215,225.00
- Revenue This Year
- CANF $409.56
- GIPR N/A
- Revenue Next Year
- CANF N/A
- GIPR $1.14
- P/E Ratio
- CANF N/A
- GIPR N/A
- Revenue Growth
- CANF N/A
- GIPR 72.92
- 52 Week Low
- CANF $1.29
- GIPR $1.50
- 52 Week High
- CANF $4.69
- GIPR $4.64
- Technical
- Relative Strength Index (RSI)
- CANF 64.57
- GIPR 45.65
- Support Level
- CANF $1.45
- GIPR $1.70
- Resistance Level
- CANF $1.50
- GIPR $2.06
- Average True Range (ATR)
- CANF 0.12
- GIPR 0.09
- MACD
- CANF 0.05
- GIPR 0.00
- Stochastic Oscillator
- CANF 66.67
- GIPR 17.07
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About GIPR Generation Income Properties Inc.
Generation Income Properties Inc is an internally managed real estate investment company focused on acquiring and managing income-producing retail, office and industrial properties net leased to high-quality tenants in major markets throughout the United States. Its key source of revenue is the rental income. The company holds properties in Alabama, Arizona, Colorado, the District of Columbia, Florida, Illinois, North Carolina and Virginia.